New Patent for Insomnia Drug Intermezzo

Transcept Pharmaceuticals Inc. March 23 announced the Patent and Trademark Office issued a second patent for the composition and use of Intermezzo (zolpidem tartrate sublingual tablet).

The Point Richmond, Calif.-based company said the patent’s number is 7,682,628, and it is titled “Compositions for Delivering Hypnotic Agents Across the Oral Mucosa and Methods of Use Thereof.” The expiration date is February 2025, the company said.

Transcept submitted a new drug application to the Food and Drug Administration for Intermezzo in September 2008, seeking approval to market the drug for the treatment of insomnia when a middle-of-the-night awakening is followed by ...